# Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS)

> **NCT01065129** · PHASE1 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 28 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** G-CSF
- **DRUG:** Plerixafor
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT01065129
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09-02
- **Primary completion:** 2014-07
- **Final completion:** 2016-10-18
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2017-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01065129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01065129, "Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01065129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*